

CURRENT REPORT 07/2022

February 1, 2022

Changes in the Issuer's Management Board

The Management Board of Selvita S.A. with its registered office in Krakow ("Issuer"), hereby informs that Issuer's Supervisory Board, acting pursuant to art. 368 par. 4 of the Polish Commercial Companies Code, appointed on January 31st, 2022 Ms. Adrijana Vinter the Management Board Member of the Issuer, effective February 1st, 2022.

Ms. Adrijana Vinter currently holds the position of Managing Director of Fidelta d.o.o., based in Croatia, a subsidiary of the Issuer. Joining the Issuer's Management Board, Ms. Vinter will be responsible for overseeing the drug discovery services provided across the Issuer's group. Information regarding the education, qualifications and positions previously held by Ms. Adrijana Vinter, along with her past job experience, is attached to this report.

Ms. Adrijana Vinter is not listed in the Registry of Insolvent Debtors maintained on the basis of the National Court Registry act, does not engage in competition with Selvita S.A, is not a partner in civil law partnerships or limited companies which engage in such competition and is not a member of any official bodies or other legal entities which engage in such competition, except for holding office in Fidelta d.o.o.

Moreover, the Management Board of the Issuer informs that it has received a statement on resignation of Ms. Edyta Jaworska from the position of the Member of the Management Board, without specifying reasons thereof, effective January 31, 2022.

Legal basis: Art. 56 section 1 item 2 of the Act on Public Offering - current and periodic information in connection with par. 5 points 4 and 5 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required by the laws of a non-member state (Journal of Laws of 2018, item 757)

Representatives of the Issuer:

- Bogusław Sieczkowski – President of the Management Board
- Dawid Radziszewski – Management Board Member

Adrijana Vinter, PhD

Global Head of Drug Discovery, Member of the Management Board

Dr. Adrijana Vinter has held the position of Managing Director at Fidelta, now part of Selvita Group, since 2017. In February 2022, Dr. Vinter has taken the position of Global Head of Drug Discovery, and been appointed to Selvita Management Board.

As the Global Head of Drug Discovery, she is in charge of Selvita Group's Drug Discovery Segment, responsible for the strategic development of the drug discovery services offer, as well as leadership of interdisciplinary teams of researchers and overseeing of the ongoing projects to ensure the highest quality of services.

Dr. Vinter started her career in PLIVA in 2002, initially working as a scientist in the medicinal chemistry field. Following foundation of Fidelta, she moved to Business Development, which she was heading until 2017, when she took the position of Managing Director and President of the Management Board. As the Managing Director, Dr. Vinter was responsible for Fidelta's full operational management and has successfully engineered and overseen the development of its revenue stream, resulting in significant year-on-year growth.

Dr. Vinter obtained her Ph.D. in Organic Chemistry at the University of Zagreb in the field of new macrolide antibiotics. She also holds an MBA title from Cotrugli Business School, Croatia. Dr. Vinter is the author of several scientific publications.

Global Head of Drug Discovery, Członek Zarządu

Dr Adrijana Vinter od 2017 roku zajmowała stanowisko Dyrektora Zarządzającego w Fidelcie, spółce zależnej Selvity. W lutym 2022 roku dr Vinter objęła funkcję Global Head of Drug Discovery oraz została powołana do Zarządu Selvity.

Jako Global Head of Drug Discovery dr Vinter odpowiada za strategiczny rozwój oferty Grupy w obszarze odkrywania leków, zarządzanie interdyscyplinarnymi zespołami badawczymi, a także nadzór nad realizowanymi projektami, w celu zapewnienia najwyższej jakości świadczonych usług.

Adrijana Vinter rozpoczęła karierę zawodową w firmie PLIVA w 2002 roku, pracując jako naukowiec w obszarze chemii medycznej. Po utworzeniu Fidelty przeszła do działu rozwoju biznesu, którym kierowała do 2017 roku. Następnie objęła stanowisko Dyrektora Zarządzającego i Prezesa Zarządu w Fidelcie, odpowiadając za zarządzanie operacyjne w spółce z powodzeniem nadzorowała rozwój organiczny chorwackiej Spółki, przyczyniając się do wzrostu jej przychodów.

Dr Vinter uzyskała stopień naukowy doktora chemii organicznej w obszarze nowych antybiotyków makrolidowych na Uniwersytecie w Zagrzebiu, a także dyplom MBA w Cotrugli Business School w Chorwacji. Dr Vinter jest autorem wielu publikacji naukowych.